Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms

Blood Cancer Journal

Volumn 1, Issue 10, 2011, Pages

  Rice, K L ^a   Lin, X ^a   Wolniak, K ^a   Ebert, B L ^b   Berkofsky Fessler, W ^c   Buzzai, M ^d   Sun, Y ^e   Xi, C ^e   Elkin, P ^e   Levine, R ^f   Golub, T ^g   Gilliland, D G ^h   Crispino, J D ^a   Licht, J D ^a   Zhang, W ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Novartis   (Italy)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g HARVARD UNIVERSITY   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

JAK2V617F; Myeloproliferative neoplasms; NFIB; SNP

Indexed keywords

BRM PROTEIN; EZH1 PROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 14; MLLT3 PROTEIN; PROTEIN; STAT5B PROTEIN; SUZ12 PROTEIN; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CELL PROTECTION; CHROMOSOME 17Q; CHROMOSOME 18P; CHROMOSOME 1P; CHROMOSOME 9; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MOUSE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PARTIAL TRISOMY 9; POLYCYTHEMIA VERA; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTHEMIA;

EID: 84864094609     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010; 91: 165-173.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
3. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007; 17: 8-14. (Pubitemid 46109298)
4. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998; 10: 271-278. (Pubitemid 28286953)
5. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008; 59: 213-222. (Pubitemid 351287934)
6. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
7. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106: 3374-3376. (Pubitemid 41609168)
8. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
9. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-22792. (Pubitemid 40853184)
10. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379. (Pubitemid 47026857)
11. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
12. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
13. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369-370.
14. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763-771. (Pubitemid 32524401)
15. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002; 108: 55-65. (Pubitemid 34983834)
16. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A et al. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008; 80: 197-200. (Pubitemid 351253455)
17. Tefferi A, Sirhan S, Sun Y, Lasho T, Finke CM, Weisberger J et al. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. Leuk Res 2009; 33: 662-664.
18. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
19. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764. (Pubitemid 46582031)
20. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011; 118: 167-176.
21. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141. (Pubitemid 43726824)
22. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004; 5: 557-572. (Pubitemid 41180205)
23. Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA et al. Inferring loss-of-heterozygosity from unpaired tumors using highdensity oligonucleotide SNP arrays. PLoS Comput Biol 2006; 2: e41.
24. Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V, Min DJ et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 2010; 16: 4339-4352.
25. Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells 2007; 25: 165-173. (Pubitemid 46052987)
26. Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF. Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype. Thromb Haemost 2005; 94: 412-421. (Pubitemid 41122497)
27. Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliafico E et al. Gene expression profiling of normal and malignant CD34- derived megakaryocytic cells. Blood 2004; 104: 3126-3135. (Pubitemid 39507126)
28. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, Lodish HF. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 1991; 11: 1980-1987. (Pubitemid 21895567)
29. Stegelmann F, Bullinger L, Griesshammer M, Holzmann K, Habdank M, Kuhn S et al. High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica 2010; 95: 666-669.
30. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
31. Forsberg EC, Passegue E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM et al. Molecular signatures of quiescent, mobilized and leukemiainitiating hematopoietic stem cells. PLoS One 2010; 5: e8785.
32. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546-554. (Pubitemid 41713996)
33. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435-2437. (Pubitemid 44497530)
34. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
35. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 2000; 102: 221-231.
36. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
37. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 2008; 19: 414-422.
38. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95: 3765-3770. (Pubitemid 30412848)
39. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109: 4924-4929. (Pubitemid 46827790)
40. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-236. (Pubitemid 34203729)
41. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102: 1869-1871. (Pubitemid 37022585)
42. Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adelaide J et al. Alterations of NFIA in chronic malignant myeloid diseases. Leukemia 2009; 23: 583-585.
43. Pina C, May G, Soneji S, Hong D, Enver T. MLLT3 regulates early human erythroid and megakaryocytic cell fate. Cell Stem Cell 2008; 2: 264-273. (Pubitemid 351298593)
44. Iida S, Seto M, Yamamoto K, Komatsu H, Tojo A, Asano S et al. MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. Oncogene 1993; 8: 3085-3092. (Pubitemid 23312915)
45. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32: 491-502.
46. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461: 819-822.
47. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112: 1402-1412.
48. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010; 115: 2882-2890.